CRIS Current Research Information System

DI STEFANO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.687
NA - Nord America 4.584
EU - Europa 3.194
AF - Africa 265
SA - Sud America 237
Continente sconosciuto - Info sul continente non disponibili 199
OC - Oceania 12
Totale 13.178
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.480
VN - Vietnam 1.315
CN - Cina 1.252
SG - Singapore 1.126
IT - Italia 1.004
GB - Regno Unito 567
DE - Germania 286
HK - Hong Kong 260
SE - Svezia 229
IN - India 207
FR - Francia 182
BR - Brasile 179
UA - Ucraina 144
KR - Corea 140
CH - Svizzera 125
RU - Federazione Russa 125
IE - Irlanda 119
FI - Finlandia 88
JP - Giappone 87
TG - Togo 85
NL - Olanda 84
BD - Bangladesh 82
CI - Costa d'Avorio 60
CA - Canada 57
ZA - Sudafrica 46
BG - Bulgaria 44
EE - Estonia 36
PH - Filippine 32
AT - Austria 30
JO - Giordania 29
MX - Messico 27
NG - Nigeria 26
TW - Taiwan 26
AR - Argentina 23
ES - Italia 23
BE - Belgio 22
SC - Seychelles 22
TR - Turchia 22
ID - Indonesia 21
PL - Polonia 21
IQ - Iraq 20
TH - Thailandia 19
DK - Danimarca 15
GR - Grecia 11
HR - Croazia 11
SA - Arabia Saudita 10
AU - Australia 9
EC - Ecuador 9
MA - Marocco 9
IR - Iran 7
LT - Lituania 6
PK - Pakistan 6
PY - Paraguay 6
CO - Colombia 5
JM - Giamaica 5
RO - Romania 5
VE - Venezuela 5
CL - Cile 4
EG - Egitto 4
LB - Libano 4
NI - Nicaragua 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DZ - Algeria 3
IL - Israele 3
MD - Moldavia 3
NP - Nepal 3
PE - Perù 3
PT - Portogallo 3
UZ - Uzbekistan 3
CZ - Repubblica Ceca 2
ET - Etiopia 2
KE - Kenya 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
RS - Serbia 2
SI - Slovenia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BH - Bahrain 1
BT - Bhutan 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GF - Guiana Francese 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
LY - Libia 1
ME - Montenegro 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NC - Nuova Caledonia 1
Totale 12.973
Salva come PNG Salva come JPEG
Città #
Singapore 819
Ashburn 571
Southend 442
Fairfield 374
Chandler 323
Bologna 321
Ho Chi Minh City 301
Hefei 298
Hanoi 280
Hong Kong 237
Santa Clara 225
San Jose 224
Woodbridge 202
Wilmington 170
Houston 165
Seattle 163
Beijing 135
Ann Arbor 122
Dublin 117
Bern 116
Seoul 113
Cambridge 105
Princeton 100
Dong Ket 94
Council Bluffs 93
Los Angeles 91
Jacksonville 89
Boardman 85
Lomé 85
New York 81
Dallas 79
Helsinki 70
Tokyo 69
Milan 68
Lauterbourg 66
Abidjan 60
Nanjing 49
Da Nang 47
Redmond 46
Sofia 43
Westminster 41
Haiphong 40
Buffalo 39
Padova 39
Bengaluru 37
Genoa 33
Berlin 31
Shenyang 30
Rome 29
Frankfurt am Main 28
Guangzhou 28
Turin 28
Amman 27
Shanghai 25
Abeokuta 24
Jinan 24
Amsterdam 22
San Diego 22
São Paulo 22
Tianjin 21
Falkenstein 20
Brussels 19
Changsha 19
Hangzhou 19
London 19
Redondo Beach 19
Saint Petersburg 19
Chicago 18
Quận Bình Thạnh 18
Thái Nguyên 18
Düsseldorf 17
Montreal 17
Vienna 17
Warsaw 17
Florence 16
Nanchang 16
Mülheim 15
Phoenix 15
Baghdad 14
Can Tho 14
Hải Dương 14
Nuremberg 14
Biên Hòa 13
Chennai 13
Falls Church 13
Jakarta 13
Mahé 13
Redwood City 13
Rimini 13
Verona 13
Wanchai 13
Zhengzhou 13
Copenhagen 12
Munich 12
Ninh Bình 12
Paris 12
Salt Lake City 12
The Dalles 12
Toronto 12
Yubileyny 12
Totale 8.328
Salva come PNG Salva come JPEG
Nome #
A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer 364
Lactate-Induced HBEGF Shedding and EGFR Activation: Paving the Way to a New Anticancer Therapeutic Opportunity 317
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib 284
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells 277
Insights into the activity of ARN24089, a new RAD51-BRCA2 disruptor that inhibits homologous recombination and achieves synthetic lethality in pancreatic cancer 264
Lactate preserves genome integrity and extends proliferative potential in cancer cells 260
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity 252
A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. 245
Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment 241
Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy. 238
Altered glycosylation profile of purified plasma ACT from Alzheimer's disease. 230
Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells 230
Uso di coniugati della doxorubicina con albumina lattosaminata 229
Preomic profile of BxPC-3 cells after treatment with BRC4 228
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. 227
Identification and subsequent development of RAD51-BRCA2 disruptors through a fragment-based approach 226
LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells 222
Lactate is a potential promoter of tamoxifen resistance in MCF7 cells 221
Liver targeted doxorubicin: effects on rat regenerating hepatocytes. 219
Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. 218
The activation of lactate dehydrogenase induced by mTOR drives neoplastic change in breast epithelial cells 218
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer 213
Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. 213
Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes. 208
Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines. 204
Galloflavin (CAS 568-80-9), a novel inhibitor of lactate dehydrogenase. 203
Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin 202
Differential enantiomers activity of ARN24089 to achieve synthetic lethality in pancreatic cancer 201
Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. 199
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors 199
A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentation grade. 197
Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. 196
Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A 195
Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. 193
Allosteric transitions of rabbit skeletal muscle lactate dehydrogenase induced by pH-dependent dissociation of the tetrameric enzyme 190
Peptides inhibiting the assembly of monomeric human l‐lactate dehydrogenase into catalytically active homotetramer decrease the synthesis of lactate in cultured cells 188
Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulationin Burkitt lymphoma cells via NAD/NADH-dependent inhibition of sirtuin-1 187
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. 186
Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. 186
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. 183
Metabolic activation triggered by cAMP in MCF-7 cells generates lethal vulnerability to combined oxamate/etomoxir 178
Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. 173
Procedura per la preparazione di coniugati della doxorubicina con l’albumina umana lattosaminata 172
Albumin-drug conjugates in the treatment of hepatic disorders. 172
The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination 171
The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially higher than that in liver and bone marrow. 170
Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. 168
Lactate Can Modulate the Antineoplastic Effects of Doxorubicin and Relieve the Drug's Oxidative Damage on Cardiomyocytes 166
Lactate Upregulates the Expression of DNA Repair Genes, Causing Intrinsic Resistance of Cancer Cells to Cisplatin 159
Elevated plasma levels of alpha-1-antichymotripsin in age-related cognitive decline and Alzheimer's disease; a poential therapeutci target. 156
Process for the preparation of doxorubicin conjugates with lactosaminated human albumin 154
Doxorubicin coupled to lactosaminated albumin: enhanced drug levels in rat hepatocarcinomas. 146
Use of conjugates of doxorubicin with lactosaminated albumin. 144
Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors 139
Human lactate dehydrogenase A undergoes allosteric transitions under pH conditions inducing the dissociation of the tetrameric enzyme 137
Lactosaminated human albumin: a hepatotropic carrier of drugs. 135
Proteomic profile of BxPC-3 cells after treatment with BRC4 134
NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases 134
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy 123
Lactate dehydrogenase inhibition: Exploring possible applications beyond cancer treatment 123
Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series 117
Inhibition of lactate dehydrogenase activity as an approach to cancer therapy 111
A Metabolites' Interplay Can Modulate DNA Repair by Homologous Recombination 106
null 101
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in cancer treatment 89
RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer 89
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy 83
Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues 79
null 78
null 71
Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas 68
Design and synthesis of RAD51-BRCA2 disruptors to inhibit homologous recombination and synergize with Olaparib as new anticancer drug discovery concept 66
Postnatal development of rat colon epithelial cells is associated with changes in the expression of the beta 1,4-N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen of alpha 2,6-sialyltransferase activity towards N-acetyl-lactosamine 62
null 51
Totale 13.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.117
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022876 0 19 76 84 74 45 42 73 39 66 190 168
2022/20231.365 111 219 50 154 115 89 40 51 207 38 71 220
2023/2024670 89 79 46 57 41 121 66 37 15 41 22 56
2024/20251.896 108 167 119 159 335 103 148 81 66 138 117 355
2025/20265.208 710 512 428 458 469 217 407 168 993 365 202 279
2026/2027253 139 114 0 0 0 0 0 0 0 0 0 0
Totale 13.178